VEGFA and neoplasm: While further studies are required to unravel the underlying mechanisms, our study, using a highly vascular mouse model of malignant glioma, provides the first direct in vivo evidence that proteasome inhibition greatly enhances the anti-tumor/anti-angiogenic effect of a VEGF/PDGF RTK inhibitor.